Elizabeth A. Sonntag, MD, Keyur B. Shah, MD, and Jason N. Katz, MD
Devices alter heart failure etiology, and specialists must navigate more ethical complexity than ever. How should curricula evolve to help them respond?
AMA J Ethics. 2019;21(5):E407-415. doi:
10.1001/amajethics.2019.407.
Rachel Koch, MD, John G. Meara, MD, DMD, MBA, and Anji E. Wall, MD, PhD
Single-procedure interventions with minimal follow-up and clear quality-of-life gain are well suited for surgical mission trips. But not all risks and benefits are easily assessed.
AMA J Ethics. 2019;21(9):E729-734. doi:
10.1001/amajethics.2019.729.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Case-based teaching, longitudinal application, and training in ethical deliberation can better prepare physicians to responsibly prescribe and manage opioids.
AMA J Ethics. 2019;21(8):E636-641. doi:
10.1001/amajethics.2019.636.